1. Catalog
  2. New Treatment Paradigms: Alfapump
New Treatment Paradigms: Alfapump
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $25.00
Patient: $0.00
Associate: $0.00
Student: $0.00
Early Career: $0.00
Industry Rep: $25.00
Credit Offered
0.25 AMA PRA Category 1 Credit
0.25 Attendance Credit
0.25 Participation Credit
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Recommended
Description: Ascites is an early and common complication of decompensated cirrhosis. The FDA approval of the Alfapump system presents a new option for treating ascites, providing a different option to improve quality of life for patients with cirrhosis. In this interview, Drs. Jasmohan Baja and Catherine Lucero discuss the optimal criteria for patient selection, perioperative and postoperative complications, the impact of quality of life and long-term outcomes for incorporating this new option into clinical practice.

COPYRIGHT: All faculty in this activity have given their permission for publication ©2024 AASLD.
Upon completion of this activity, participants should be able to:
  • Describe the indications for appropriate use of the Alfapump system in the treatment of ascites.
  • Discuss the impact of this new treatment modality on the care of patients with decompensated cirrhosis.
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: 9/19/2025
Expiration Date: 9/19/2027
This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Catherine Lucero, MD
Nothing to Disclose

Jasmohan Bajaj, MD, FAASLD
Grant/Research Support:  Bausch, Sequana, Grifols, Genfit
Advisor: Enterobiotix, Boehringer Ingelheim


STAFF

Steve Folstein MFA M.Ed.
Nothing to Disclose

Wendy Risso, MPH
Nothing to Disclose
Powered By